Progression from mild cognitive impairment to Alzheimer's disease: Effects of sex, butyrylcholinesterase genotype, and rivastigmine treatment

Pharmacogenetics and Genomics

Volumn 19, Issue 8, 2009, Pages 635-646

  Ferris, Steven ^a   Nordberg, Agneta ^c   Soininen, Hilkka ^d   Darreh Shori, Taher ^c   Lane, Roger ^b  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b NOVARTIS PHARMA AG   (Switzerland)

^c KAROLINSKA INSTITUTE   (Sweden)

^d KUOPIO UNIVERSITY HOSPITAL   (Finland)

Author keywords

Butyrylcholinesterase; Mild cognitive impairment; Rivastigmine

Indexed keywords

BUTYRYLCHOLINESTERASE E; CHOLINESTERASE; ESTERASE; PLACEBO; RIVASTIGMINE; UNCLASSIFIED DRUG;

AGED; ALZHEIMER DISEASE; ARTICLE; BRAIN ATROPHY; BRAIN SIZE; BRAIN VENTRICLE; CLINICAL EVALUATION; CLINICAL TRIAL; COGNITIVE DEFECT; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE COURSE; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; ENZYME ACTIVITY; FEMALE; GENE FREQUENCY; GENOTYPE; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MALE; MENTAL DETERIORATION; MULTICENTER STUDY; NUCLEAR MAGNETIC RESONANCE IMAGING; PHARMACOGENETICS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RETROSPECTIVE STUDY; SEX DIFFERENCE; TREATMENT DURATION; TREATMENT RESPONSE; WHITE MATTER; WILD TYPE;

ALZHEIMER DISEASE; BIOLOGICAL MARKERS; BUTYRYLCHOLINESTERASE; CHOLINESTERASE INHIBITORS; COGNITION; COGNITION DISORDERS; DISEASE PROGRESSION; FEMALE; GENOTYPE; HUMANS; MALE; NEUROPROTECTIVE AGENTS; PHARMACOGENETICS; PHENYLCARBAMATES; PLACEBOS; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 68849109872     PISSN: 17446872     EISSN: 17446880     Source Type: Journal    
DOI: 10.1097/FPC.0b013e32832f8c17     Document Type: Article

References (50)

1. Feldman HH, Ferris S, Winblad B, Sfikas N, Mancione L, He Y, et al. Effect of rivastigmine on delay to diagnosis of Alzheimer's disease from mild cognitive impairment: the InDDEx study. Lancet Neurol 2007; 6:501-512.
2. Ferris S, Lane R, Sfikas N, Winblad B, Farlow M, Feldman H. Treatment response to rivastigmine in Mild Cognitive Impairment: an enhanced statistical modeling approach. Gender Med 2009 (in press).
3. Darreh-Shori T, Almkvist O, Guan ZZ, Garlind A, Strandberg B, Svensson AL, et al. Sustained Cholinesterase inhibition in AD patients receiving rivastigmine for 12 months. Neurology 2002; 59:563-572.
4. Bartzokis G, Lu PH, Geschwind DH, Tingus K, Huang D, Mendez MF, et al. Apolipoprotein E affects both myelin breakdown and cognition: implications for age-related trajectories of decline into dementia. Biol Psychiatr 2007; 62:1380-1387.
5. Venneri A, Lane R. Effects of Cholinesterase inhibition on brain white matter volume in Alzheimer's disease. Neuroreport 2009; 20:285-288.
6. Mohs RC, Rosen WG, Davis KL. The Alzheimer's disease assessment scale: an instrument for assessing treatment efficacy. Psychopharmacol Bull 1983; 19:448-450.
7. Galasko D, Bennett D, Sano M, Ernesto C, Thomas R, Grundman M, et al. An inventory to assess activities of daily living for clinical trials in Alzheimer's disease. The Alzheimer's Disease Cooperative Study. Alzheimer Dis Assoc Disord 1997; 11 (Suppl 2):S33-S39.
8. Rust S, Funke H, Assmann G. Mutagenically separated PCR (MS-PCR): a highly specific one step procedure for easy mutation detection. Nucleic Acids Res 1993; 21:3623-3629.
9. Ellman GL, Courtney KD, Andres V Jr, Feather-Stone RM. A new and rapid colorimetric determination of acetylcholinesterase activity. Biochem Pharmacol 1961; 7:88-95.
10. Darreh-Shori T, Brimijoin S, Kadir A, Almkvist O, Nordberg A. Differential CSF butyrylcholinesterase levels in Alzheimer's disease patients with the ApoE epsilon4 allele, in relation to cognitive function and cerebral glucose metabolism. Neurobiol Dis 2006; 24:326-333.
11. Styner M, Charles H, Park J, Gerig G. Multi-site validation of image analysis methods: Assessing intra and inter-site variability. Proceedings of SPIE. Medical Imaging: Image Processing, Milan Sonka. J Michael Fitzpatrick (Editors), 4684:2002. pp. 278-286.
12. Schott JM, Price SL, Frost C, Whitwell JL, Rossor MN, Fox NC. Measuring atrophy in Alzheimer disease: a serial MRI study over 6 and 12 months. Neurology 2005; 65:119-124.
13. Fox NC, Freeborough PA. Brain atrophy progression measured from registered serial MRI: validation and application to Alzheimer's disease. J Magn Reson Imaging 1997; 7:1069-1075.
14. Lane R, Feldman HH, Meyer J, He Y, Ferris SH, Nordberg A, et al. Synergistic effect of apolipoprotein E ε4 and butyrylcholinesterase K-variant on progression from mild cognitive impairment to Alzheimer's disease. Pharmacogenet Genomics 2008; 18:289-298.
15. Fleisher A, Grundman M, Jack CR Jr, Petersen RC, Taylor C, Kim HT, et al. Sex, apolipoprotein E epsilon 4 status, and hippocampal volume in mild cognitive impairment. Arch Neurol 2005; 62:953-957.
16. Barnes LL, Wilson RS, Bienias JL, Schneider JA, Evans DA, Bennett DA. Sex differences in the clinical manifestations of Alzheimer disease pathology. Arch Gen Psychiatr 2005; 62:685-691.
17. Webber KM, Casadesus G, Marlatt MW, Perry G, Hamlin CR, Atwood CS, et al. Estrogen bows to a new master: the role of gonadotropins in Alzheimer pathogenesis. Ann N Y Acad Sci 2005; 1052:201-209.
18. Kovalev V, Kruggel F. Texture anisotropy of the brain's white matter as revealed by anatomical MRI. IEEE Trans Med Imag 2007; 26:678-685.
19. Hsu JL, Leemans A, Bai CH, Lee CH, Tsai YF, Chiu HC, et al. Gender differences and age-related white matter changes of the human brain: a diffusion tensor imaging study. Neuroimage 2008; 39:566-577.
20. Ringman JM, O'Neill J, Geschwind D, Medina L, Apostolova LG, Rodriguez Y, et al. Diffusion tensor imaging in preclinical and presymptomatic carriers of familial Alzheimer's disease mutations. Brain 2007; 130:1767-1776.
21. Cosgrove KP, Mazure CM, Staley JK. Evolving knowledge of sex differences in brain structure, function, and chemistry. Biol Psychiatr 2007; 62:847-855.
22. Miyashita A, Arai H, Asada T, Imagawa M, Matsubara E, Shoji M, et al. Genetic association of CTNNA3 with late-onset Alzheimer's disease in females. Human Mol Genet 2007; 16:2854-2869.
23. Zylberstein DE, Lissner L, Björkelund C, Mehlig K, Thelle DS, Gustafson D, et al. Midlife homocysteine and late-life dementia in women. A prospective population study. Neurobiol Aging 2009 [Epub ahead of print].
24. Lane R, He Y Emerging hypotheses regarding the influences of butyrylcholinesterase-K variant, APOE e4, and hyperhomocysteinemia in neurodegenerative dementias. Medical Hypotheses 2009; 73:230-250.
25. Diamant S, Podoly E, Friedler A, Ligumsky H, Livnah O, Soreq H. Butyrylcholinesterase attenuates amyloid fibril formation in vitro. Proc Natl Acad Sci U S A 2006; 103:8628-8633.
26. Bradamante V, Kunec-Vajic E. Effect of glucocorticoids on plasma Cholinesterase in the rat. Biomed Biochim Acta 1987; 46:439-443.
27. Perry EK, Perry RH, Blessed G, Tomlinson BE. Changes in brain cholinesterases in senile dementia of Alzheimer type. Neuropathoi Appi Neurobiol 1978; 4:273-277.
28. Hu J, Van Eldik LJ. Glial-derived proteins activate cultured astrocytes and enhance beta amyloid-induced glial activation. Brain Res 1999; 842:46-54.
29. Darreh-Shori T, Forsberg A, Andreasen N, Blennow K, Wall A, Kamil C, et al. Interaction between amyloid-beta peptides with butyrylcholinesterase and APOE proteins: mechanism of amyloid fibrils deposition in the brain of patients with Alzheimer's disease. Poster Presented at the 11th International Conference on Alzheimer's Disease. Chicago, IL, USA, 26-31 July 2008.
30. Tasker A, Ballard CG, Joachim C, Warden DR, Okello EJ, Perry RH, et al. Butyrylcholinesterase K variant associated with higher enzyme activity in the temporal cortex of elderly patients. Neurosci Lett 2008; 442:297-299.
31. Mesulam M, Guillozet A, Shaw P, Quinn B. Widely spread butyrylcholinesterase can hydrolyze acetylcholine in the normal and Alzheimer brain. Neurobiol Dis 2002; 9:88-93.
32. Greig NH, Utsuki T, Ingram DK, Wang Y, Pepeu G, Scali C, et al. Selective butyrylcholinesterase inhibition elevates brain acetylcholine, augments learning and lowers Alzheimer beta-amyloid peptide in rodent. Proc Natl Acad Sci U S A 2005; 102:17213-17218.
33. Cerbai F, Giovannini MG, Melani C, Enz A, Pepeu G. N1 phenethyl-norcymserine, a selective butyrylcholinesterase inhibitor, increases acetylcholine release in rat cerebral cortex: a comparison with donepezil and rivastigmine. Eur J Pharmacol 2007;572:142-150.
34. Ben-Shaul Y, Bergman H, Soreq H. Acetylcholinesterase, cholinergic signaling and Parkinson's disease. In: Hanin I, Cacabelos R, Fisher A, editors. Recent Progress in Alzheimer's and Parkinson's diseases. London and New York: Taylor & Francis; 2005. pp. 33-44.
35. Huang J, Friedland RP, Auchus AP Diffusion tensor imaging of normal-appearing white matter in mild cognitive impairment and early Alzheimer disease: preliminary evidence of axonal degeneration in the temporal lobe. AJNR Am J Neuroradiol 2007; 28:1943-1948.
36. Nizri E, Irony-Tur-Sinai M, Faranesh N, Lavon I, Lavi E, Weinstock M, et al. Suppression of neuroinflammation and immunomodulation by the acetylcholinesterase inhibitor rivastigmine. J Neuroimmunol 2008; 203:12-22.
37. Wright CI, Geula C, Mesulam MM. Neurological cholinesterases in the normal brain and in Alzheimer's disease: relationship to plaques, tangles, and patterns of selective vulnerability. Ann Neurol 1993; 34:373-384.
38. Bullock R, Lane R. Executive dyscontrol in dementia, with emphasis on subcortical pathology and the role of butyrylcholinesterase. Curr Alzheimer Res 2007; 4:277-293.
39. Rozzini L, Chilovi BV, Conti M, Bertoletti E, Delrio I, Trabucchi M, et al. Conversion of amnestic Mild Cognitive Impairment to dementia of Alzheimer type is independent to memory deterioration. Int J Geriatr Psychiatr 2007; 22:1217-1222.
40. Blesa R, Bullock R, He Y, Bergman H, Gambina G, Meyer J, et al. Effect of butyrylcholinesterase genotype on the response to rivastigmine or donepezil in younger patients with Alzheimer's disease. Pharmacogenet Genomics 2006; 16:771-774.
41. Touchon J, Bergman H, Bullock R, Rapatz G, Nagel J, Lane R. Response to rivastigmine or donepezil in Alzheimer's patients with symptoms suggestive of concomitant Lewy body pathology. Curr Med Res Opin 2006; 22:49-59.
42. Longstreth WT Jr, Arnold AM, Manolio TA, Burke GL, Bryan N, Jungreis CA, et al. Clinical correlates of ventricular and sulcal size on cranial magnetic resonance imaging of 3301 elderly people. The Cardiovascular Health Study. Collaborative Research Group. Neuroepidemiology 2000; 19:30-42.
43. Carmichael OT, Kuller LH, Lopez OL, Thompson PM, Dutton RA, Lu A, et al. Ventricular volume and dementia progression in the Cardiovascular Health Study. Neurobiol Aging 2007; 28:389-397.
44. Venneri A, McGeown WJ, Shanks MF. Empirical evidence of neuroprotection by dual Cholinesterase inhibition in Alzheimer's disease. Neuroreport 2005; 16:107-110.
45. Farlow M, Potkin S, Koumaras B, Veach J, Mirski D. Analysis of outcome in retrieved dropout patients in a rivastigmine vs placebo, 26-week, Alzheimer disease trial. Arch Neurol 2003; 60:843-848.
46. Erkinjuntti T, Román G, Kalaria R, Lane R. Mechanisms of action and treatment benefits with Cholinesterase inhibitors with vascular cognitive disorders. J Drug Assess 2005; 8:61-77.
47. Erkinjuntti T, Skoog I, Lane R, Andrews C. Potential long-term effects of rivastigmine on disease progression may be linked to drug effects on vascular changes in Alzheimer brains. Int J Clin Pract 2003; 57:756-760.
48. Doraiswamy PM, Krishnan KR, Anand R, Sohn H, Danyluk J, Hartman RD, et al. Long-term effects of rivastigmine in moderately severe Alzheimer's disease: does early initiation of therapy offer sustained benefits? Prog Neuropsychopharmacol Biol Psychiatr 2002; 26:705-712.
49. Farlow M, Anand R, Messina J Jr, Hartman R, Veach J. A 52-week study of the efficacy of rivastigmine in patients with mild to moderately severe Alzheimer's disease. Eur Neurol 2000; 44:236-241.
50. Agid Y, Dubois B, Anand R, Gharabawi G. International Rivastigmine Investigators. Efficacy and tolerability of rivastigmine in patients with dementia of the Alzheimer type. Curr Therap Res 1998; 59:837-845.